Podcasts about LP

Brandon Sedloff sits down with Mike Boggs of Revelation Partners and Justin Burden of Industry Ventures at the Venture Secondaries Summit to explore how venture secondaries have evolved from a tool for distressed sellers into an institutional liquidity engine for private markets. The conversation examines the specialist approach required to succeed in this opaque, relationship-driven market where transactions happen by appointment rather than on open exchanges. They discuss: - Why venture secondaries function as a third liquidity option beyond IPOs and M&A, particularly in healthcare where billion-dollar outcomes are considered large - How secondary buyers navigate competition from insider investors by serving as arm's-length pricing partners for founder share sales - The structural liquidity problem created by over $800 billion in unrealized healthcare value and trillions locked in tech, with secondary funds positioned to address this overhang - Why specialization in specific sectors or deal types is becoming essential as commoditization pressures generalist secondary funds - How the flight to quality means focusing capital on late-stage, proven companies rather than indexing across venture portfolios This episode offers private markets investors and operators a practical view of how venture secondaries create value in an environment where companies stay private longer and traditional exit paths remain constrained. Topics: (00:00:00) - Intro (00:00:29) - Guest introductions and firm backgrounds (00:04:47) - Evolution of venture secondaries as liquidity (00:07:20) - What happens if IPOs and M&A return (00:11:28) - Specialists versus generalists in secondaries (00:13:04) - Secondaries as asset class or strategy (00:17:07) - Overcoming discount buyer perceptions (00:19:47) - Building conviction and underwriting (00:22:58) - Navigating competition from top VCs (00:25:32) - Educating the market on secondary options (00:29:52) - Liquidity challenges for the messy middle (00:33:17) - Transfer rights and insider preferences (00:38:22) - LP secondaries market maturation concerns (00:40:15) - Outlooks on the next 5 to 10 years (00:44:04) - What could stop the growth trajectory (00:47:42) - Competition and differentiation challenges (00:50:49) - Closing Links: Mike Boggs on LinkedIn - https://www.linkedin.com/in/michael-boggs-7921343/ Justin Burden on LinkedIn - https://www.linkedin.com/in/justin-burden-46120a/ Brandon Sedloff on LinkedIn - https://www.linkedin.com/in/brandonsedloff/ Revelation Partners - https://revelation-partners.com/ Industry Ventures - https://www.industryventures.com/ Juniper Square - https://www.junipersquare.com/

The newest AHA and ACC guidelines for treating dyslipidemia are here — and according to Dr. Kim Williams, they mark a powerful shift toward prevention, earlier testing, and whole-food, plant-based nutrition as the foundation of cardiovascular care.Rip welcomes back Dr. Kim Williams, past president of the American College of Cardiology, for a practical and deeply encouraging breakdown of what these updated cholesterol guidelines mean for everyday people.Dr. Williams explains why cardiovascular risk is no longer just about one cholesterol number. Instead, clinicians are being encouraged to look at the whole picture: LDL cholesterol, ApoB, Lp(a), inflammation, blood pressure, blood sugar, kidney function, family history, lifestyle, and coronary artery calcium when appropriate.The most exciting part for the PlantStrong community? Lifestyle optimization is now treated as the clinical foundation — and Dr. Williams is clear about what that means: a whole-food, plant-based diet built around beans, grains, nuts, seeds, fruits, vegetables, and mushrooms, along with exercise, sleep, mindfulness, strong social connections, and avoidance of tobacco, alcohol, and other harmful substances.This conversation also tackles statins, PCSK9 inhibitors, Lp(a), coronary calcium scoring, and the new philosophy of treating risk lower, earlier, and longer — always with food first, and medication when needed.Key TakeawaysThe new cholesterol guidelines emphasize lifestyle first, not lifestyle as an afterthought.Dr. Williams says a whole-food, plant-based diet should be built around beans, grains, nuts, seeds, fruits, vegetables, and mushrooms.LDL cholesterol is still important, but it is no longer the only number that matters.ApoB may give a clearer picture of risk in some people, especially those with diabetes, high triglycerides, or central obesity.Lp(a) is largely genetic and should be measured at least once in adulthood; the 2026 guideline includes updated recommendations for elevated Lp(a).Coronary artery calcium scoring can help personalize risk and guide LDL targets.Dr. Williams emphasizes that the goal is not “plants versus statins.” It is whole plant foods first, medications when needed.The overall prevention philosophy is: lower, earlier, longer.Watch the Episode on YouTube: https://youtu.be/6cD8tGpsAggLearn More About our 2026 Live PLANTSTRONG Events: https://plantstrongevents.com/ Let Us Help Your PLANTSTRONG JourneyLearn More About Our Corporate Wellness Program: https://liveplantstrong.com/corporate-wellness/ COMPLEMENT: Use code PLANTSTRONG for 30% off at https://lovecomplement.com/pages/plantstrong-special-offer Follow PLANTSTRONG and Rip Esselstynhttps://plantstrong.com/ https://www.facebook.com/GoPlantstrong https://www.instagram.com/goplantstrong/https://www.instagram.com/ripesselstyn/ Follow the PLANTSTRONG Podcast and Give the Show a 5-star RatingApple PodcastsSpotify

I'm delighted to have today's guest back on the podcast. When we last heard from Kris Byers, he told us about the incredible turnaround and evolution of his business since implementing the No BS Model. In eighteen months, he went from scared of investing in joining the program to quadrupling his income – with a third of the clients! I wanted to check back in with Kris because since that episode, he's won awards, bagged some really big clients, and run incredible projects. You'll want to hear about how he handled working with bigger companies and more decision makers while still getting rid of the BS. And he'll explain why he's shifting his focus back to small businesses, even though he now knows how to successfully manage the big guys.  Kris Byers is the founder of Horrible Brands, where he helps purpose-driven business owners create personal brands to show up with clarity and confidence, and create real world impact. Tune into this episode to hear:How Kris tweaked the No BS Model to accommodate bigger projects and longer timeframes without losing the guardrailsHow to successfully deputize a decision-maker to be the leader of their groupWhy the LP is even more essential when you're juggling multiple stakeholdersHow bigger project price tags can make you lose sight of your boundariesWhat Kris learned about refining his messaging Learn more about Kris Byers:Horrible Brands: http://horriblebrands.comKris's Website: https://www.krisbyers.comInstagram: @horriblebrandsConnect on LinkedIn: https://www.linkedin.com/in/krisbyers/Resources:Grab the first chapter of my new book Scale Solo: scalesolobook.comProgram: No BS Mastery: https://nobsmastery.com/programThe Price to Freedom Calculator™ - http://nobsmastery.com/priceGrab a copy of my book: Badass Your Brand - https://www.badassyourbrand.com/Program: No BS Agency Mastery: https://join.nobsmastery.com/agency-masteryNo BS Clients Lab: https://nobsclientslab.com/

Writing a book is a goal that many people talk about for years, but very few actually follow through. We convince ourselves that we'll get started when life slows down, and before you know it, years have gone by with a great idea just sitting on the back burner. As someone whose life was completely transformed by writing The Miracle Morning book series, I truly believe a book can become one of the most valuable assets you ever create. It can amplify your impact, preserve your legacy, and open doors that would never have opened otherwise. Today, I'm joined by my good friend Chandler Bolt, the founder of SelfPublishing.com and author of Published.: The Proven Path From Blank Page To 10,000 Copies Sold. Chandler has helped thousands of authors write and publish their books and, in the process, has scaled his company into an eight-figure business. In our conversation, Chandler explains why writing a book can become the best business card you'll ever create, how to leverage your book to grow your business, and how he's using AI to help authors write better books and build better companies. KEY TAKEAWAYS Why Chandler Wrote His First Book The Tragedy That Changed Chandler's Life Just Get In The Room And Get Started Why Everyone Can and Should Write A Book How A Book Preserves Your Legacy Your Book Can Grow Your Business Exponentially How Chandler Scaled An Eight-Figure Company The 4 Ps Of A High-Converting Offer Decide What You Want Your Business Looks Like Hire People Who Compliment Your Skills Chandler's Goal To Publish 100,000 Books How AI Is Changing Book Writing How Chandler Uses AI To Scale His Business  Get The Full Show Notes To get full access to today's show notes, including audio, transcript, and links to all the resources mentioned, visit MiracleMorning.com/642 Subscribe, Rate & Review I would love if you could subscribe to the podcast and leave an honest rating & review. This will encourage other people to listen and allow us to grow as a community. The bigger we get as a community, the bigger the impact we can have on the world. To subscribe, rate, and review the podcast on iTunes, visit HalElrod.com/iTunes. Get Access to Hal's Books and the Miracle Morning App For access to Hal's Miracle Morning books, CLICK HERE.  To upgrade your morning routine, CLICK HERE to download the Miracle Morning App.  Book Hal to Speak At Your Event! If you'd like to book Hal to speak at your next event, CLICK HERE. Connect with Hal Elrod Facebook Twitter Instagram LinkedIn YouTube TikTok   Copyright © 2026 Miracle Morning, LP and International Literary Properties LLC  

Hello and welcome to Aquarium Drunkard Transmissions with Jason P. Woodbury, presented by the Talkhouse Podcast Network. We're kicking off our new season with a fantastic guest: Don Was. Was' CV is stunning. In addition to his genre-bending work with Was (Not Was), Don has collaborated with some of the most respected artists in music history: Bob Dylan, Bonnie Raitt, The Rolling Stones, The B-52s, Ringo Starr, Roy Orbison…the list could go on. These days, you can find Don with his band, The Pan-Detroit Ensemble, whose latest album is called Groove in the Face of Adversity, and behind the desk at Blue Note Records—he's been the president of the legendary jazz label since 2011.  But Don has joined us today to talk about one of his very first recording projects: Ted Lucas' Impossible Love, an unheard album he cut with the cult Detroit songwriter in 1979. Impossible Love is part of Third Man Records' new collection of Lucas gold, Images of Life. Following their reissue of his stoned folk classic 1975 LP, Third Man Records has unlocked the vault, offering a comprehensive look at one of the late '60s and '70s' most dynamic Detroit talents. Spanning Lucas' career, the set includes recordings by Lucas' early regional sensations like The Spike Drivers, The Misty Wizards, and The Horny Toads, acoustic demos, and his long-lost second album, produced by Was.  Don joined us to discuss his time with Ted–including a disastrous gig they played with Black Sabbath—and help us uncover this lost Motor City counter culture story. And that's not all—Don also reflected on his work with the late bandmate Bob Weir, the legacy of the Dead, and of course, his work on Garth Brooks' ill-fated 1999 Chris Gaines project. That's right: we went there. So roll up your sleeves and let's get to it, Don Was on Transmissions.

In this episode, Chris Lopez welcomes Christine Kwasny back to the show to break down the Risk Radar, a visual due diligence tool she built to help LP investors better understand where risk shows up in a private real estate deal. The tool grew out of Christine's Substack, Net Zero Is a Win, where she publishes retrospective deal analyses on what went right, what went wrong, and what investors may have been able to identify in the original offering materials. Christine walks through the Risk Radar's three major categories: what is fixed at closing, what is sponsor driven, and what is market driven. Chris and Christine discuss how LPs can evaluate GP team history, “cockroach” risks, going-in cap rates, debt terms, reserves, expense assumptions, capital stack structure, waterfalls, exit cap rates, supply and demand, rent growth, absorption, and vacancy. They also explore why retrospective analysis is one of the best ways to test whether risk was visible up front, why market timing can dominate long-term outcomes, and how tools like AI may help investors gather better data without outsourcing their own judgment. Disclaimer The content of this podcast is for informational purposes only. All host and participant opinions are their own. Investment in any asset, real estate included, involves risk, so use your best judgment and consult with qualified advisors before investing. You should only risk capital you can afford to lose. Past performance is not indicative of future results. This podcast may contain paid advertisements or other promotional materials for real estate investment advisers, investment funds, and investment opportunities, which should not be interpreted as a recommendation, endorsement, or testimonial by PassivePockets, LLC or any of its affiliates. Viewers must conduct their own due diligence and consider their own financial situations before engaging with any advertised offerings, products, or services. PassivePockets, LLC disclaims all liability for direct, indirect, consequential, or other damages arising out of reliance on information and advertisements presented in this podcast.

Justin Smith-Lorenzetti, VP of Investments at Intact Private Capital, shares his journey from leading innovation initiatives within Intact Insurance to helping build a global investment platform managing more than $1.6 billion in assets. Drawing on lessons from investments across insurtech, mobility, AI, and financial services, he explains how Intact approaches startup and LP investing. Justin also offers practical advice for founders and investors, arguing that focus and conviction matter more than ever in today's AI-driven world. In this episode, you'll learn: [02:08] How Justin accidentally became a venture capitalist [06:55] How Intact Private Capital invests from idea to IPO [09:11] The evolution of insurtech over the last decade [11:26] Why Coterie and Shepherd stood out as investments [16:56] What Justin looks for in founders across every stage [20:23] Why founders choose investors—not the other way around [23:15] How Intact makes high-conviction investment decisions [25:17] What Justin looks for as an LP investing in venture funds [29:57] His advice for founders building in the AI era [32:17] What venture capital can do better The nonprofit organization Justin is passionate about: Lorenzetti Foundation About Justin Smith-Lorenzetti Justin Smith-Lorenzetti is VP of Investments at Intact Private Capital, where he oversees venture, growth, and fund investments across insurance, financial services, mobility, and emerging technology. Since helping launch Intact's venture investing activities more than a decade ago, he has backed companies ranging from Turo to leading insurtech startups. Justin is widely recognized as one of Canada's most active investors in the insurance technology ecosystem and serves on the boards of multiple venture-backed companies. About Intact Private Capital Intact Private Capital is the private investment arm of Intact Financial Corporation, one of North America's leading property and casualty insurance companies. The firm manages approximately $1.6 billion across venture capital, growth equity, and fund investment strategies. Leveraging Intact's deep industry expertise and global network, the team invests in companies across insurance, financial services, mobility, AI, and adjacent sectors, supporting founders from the earliest stages through IPO. Subscribe to our podcast and stay tuned for our next episode.

Tuesday is occasionally reserved for the bizarre, and we've got that for you today. The CBS Radio Workshop was an experimental program, often with programs that defied conventional tropes. Originally broadcast in April 1956, "The Record Collectors" is an over-the-top satire hosted by John Dehner. The program introduces two eccentric (and fictional) record collectors who are convinced that music peaked with 78 RPM records. As they spar with real-life musical guests including Margaret Whiting and Lynn Murray, they take aim at all the latest innovations of that day, including high fidelity sound, LP records, and just about everything else. Visit our website: https://goodolddaysofradio.com/ Subscribe to our Facebook Group for news, discussions, and the latest podcast: https://www.facebook.com/groups/881779245938297 Our theme music is "Why Am I So Romantic?" from Animal Crackers: https://www.amazon.com/dp/B01KHJKAKS/ref=cm_sw_em_r_mt_dp_MK8MVCY4DVBAM8ZK39WD

What does managing $600 billion teach you about risk that most investors never learn?Jeffrey Blazek, Co-CIO of Multi-Asset at Neuberger Berman, joins Prashant on VC10X to challenge the assumptions that have quietly shaped — and quietly undermined — institutional portfolios for a generation. From the macro shift that is more permanently broken than rates or geopolitics, to the asset class generating 10 to 15 percent returns with zero correlation to equities, to whether AI is the internet bubble all over again — this is one of the most substantive allocator conversations we have had on the show.⭐ Sponsored by Podcast10x - Podcasting agency for VCs - https://podcast10x.comIn this episode:— Why deglobalization is the one macro assumption that will not reverse— The difference between short-term volatility risk and the purchasing power risk that actually destroys portfolios— Why bonds have failed as a diversifier and what replaces them— Catastrophe bonds: the non-consensus case for an asset class most institutions will not touch— The $1B to $10B institutional sweet spot and why scale is not always an advantage— AI investment: real conviction, real concentration risk, and the winner-take-most bear case— What the private markets miscalibration of the last decade means for LP portfolios today— The off-script manager due diligence technique that separates process from performance— Career risk as the hidden driver of institutional conservatism— Where rates are headed and why the old fixed income playbook is goneJeffrey Blazek is Co-CIO of Multi-Asset at Neuberger Berman, a $600B global asset management firm with over 700 investment professionals across 30+ offices worldwide.Links:Neuberger - https://www.nb.com/Jeffrey on LinkedIn: https://www.linkedin.com/in/jeffrey-blazek-cfa-a0a57212Connect with Prashant: https://linkedin.com/in/choubeysahabSubscribe to VC10X newsletter - ⁠https://vc10x.beehiiv.com⁠Subscribe on YouTube - ⁠https://youtube.com/@VC10X ⁠Subscribe on Apple Podcasts - ⁠https://podcasts.apple.com/us/podcast/vc10x-investing-venture-capital-asset-management-private/id1632806986⁠Subscribe on Spotify - ⁠https://open.spotify.com/show/7F7KEhXNhTx1bKTBFgzv3k?si=WgQ4ozMiQJ-6nowj6wBgqQ⁠VC10X website - ⁠https://vc10x.comTimestamps:(00:00) - Preview(01:39) - Introduction to Jeffrey Blazek(03:16) - Which Macro Assumptions Are Permanently Broken Today?(05:03) - Key Drivers of Long-Term Returns Most Investors Underestimate(06:24) - Coaching Clients to Embrace Appropriate Equity Exposure(07:55) - What Real Diversification Looks Like in Practice(09:51) - How Portfolio Construction Changes as Institutions Scale(11:55) - Should Investors Change Their Approach to Equity Markets Now?(13:31) - Evaluating a New Asset Class for Permanent Allocation(15:16) - AI: A Genuine Secular Shift or a Narrative-Driven Boom?(17:26) - The Bear Case for AI: Commoditization and Concentration Risk(19:30) - Uncovering a Non-Consensus Asset Class: Catastrophe Bonds(21:09) - Common Mistakes LPs Make in Private Market Allocations(22:58) - The Key to Effective Investment Manager Selection(24:25) - Analyzing Past Portfolio Mistakes: Errors of Analysis vs. Behavior(26:24) - The Gap Between Institutional Goals and Portfolio Realities(27:38) - What Drives Over-Conservatism in Institutional Investing?(29:15) - How Investment Needs Differ Across Institutions (Hospitals vs. Endowments)(31:38) - Advising Family Capital: Avoiding Common Mistakes(33:43) - Career Lessons Learned from Navigating Market Crises(36:01) - The Most Misunderstood Risk of the 2020s(37:22) - Is the AI Boom a Repeat of the Dot-Com Bubble?(38:15) - The Three Most Important Bets for the Next Decade(40:00) - Outlook on the Future Interest Rate Environment(41:19) - Where to Find Jeffrey Blazek and Neuberger Berman

Send us Fan MailLEARN THE CAPITAL RAISING STRATEGIES AND FRAMEWORKS used by alternative asset professionals: https://go.fundraisecapital.co/applyDOWNLOAD The 23 Cognitive Biases: https://go.fundraisecapital.co/100m-blueprint-860536-648168-166304-426463-122119This episode is brought to you by Reef Pass | Serial Acquisition Investors: Reef Pass Investors has spent the last 10 years focused on partnering with founders to launch and build long-term holding companies, and has a proven track record doing exactly that.To reach out to Reef Pass Investors, email holdcofounders@reefpassinvestors.comIn the competitive realms of private equity and venture capital, general partners spend resources building complex risk models and assessments, assuming data alone drives portfolio outperformance. However, sustainable alpha is fundamentally capped by human behavior.How does anchoring bias impact private equity valuations? In this masterclass episode of Making Billions, Ryan Miller challenges managers to treat decision calibration as a compounding asset, shifting the focus from financial metrics to rigorous behavioral oversight. Discover an engineered approach to investment psychology that will redefine how you run due diligence, manage LP communication, and shield your fund from systemic blind spots.[THE HOST]: Ryan Miller is a fund manager, capital strategist, and former CFO turned angel investor in technology and energy. He is the founder of Fund Raise Capital and Aequor Capital Partners, and has mentored over 1,000 fund managers across private equity, private credit, venture capital, real estate, and alternative assets globally.Subscribe on YouTube:https://www.youtube.com/channel/UCTOe79EXLDsROQ0z3YLnu1QQConnect with Ryan Miller:Linkedin: https://www.linkedin.com/in/rcmiller1/Instagram: https://www.instagram.com/ryanmilleroffical/X: https://x.com/_MakingBillionsWebsite: https://making-billions.com/Support the showDISCLAIMER: This podcast is for entertainment and general informational purposes only — not legal, financial, tax, or investment advice. Nothing herein constitutes a solicitation or offer to buy or sell any security or investment product. Past performance does not indicate future results. Always consult qualified legal, financial, and tax professionals before making any investment decision. NAME NOTICE: "Making Billions with Ryan Miller" reflects the profile and aspirations of guests featured — it is not a promise, projection, guarantee, or representation of any financial result, income, or outcome for any listener, viewer, or reader. Most individuals who consume this content do not raise any particular amount of capital, and many achieve no financial result whatsoever. "Fund Raise Capital" is a brand identifier only — it is not a promise, guarantee, or representation that any member, subscriber, or listener will raise capital, attract investors, or achieve any financial or professional outcome. This show does not constitute a business opportunity, franchise, investment program, or offer of any product or service of any kind. No part of this show should be construed as a solicitation for investment in any way. Guest views are their own and do not necessarily reflect those of the show or host. Host and/or guests may hold positions in assets discussed. This episode may contain paid sponsorships, advertisements, or endorsements. Sponsored content is identified where...

Most of us assume that if we look healthy on the outside, our heart is fine on the inside, but today, preventive cardiology dietitian Michelle Routhenstein explains why that's exactly the assumption that gets women into trouble, especially through perimenopause and beyond. We get into the two numbers your doctor probably isn't checking, ApoB and Lp(a), the first five diet changes Michelle makes with clients to bring down high cholesterol numbers, why stretching may be doing as much for your arteries as it does for your joints, and why blood pressure, not HRV, deserves far more of your attention as you move through this life stage. WHAT YOU'LL LEARN ●      Why heart disease can silently progress in women who look and feel healthy ●      What ApoB and Lp(a) actually measure, and why they matter more than LDL and HDL alone ●      The first five diet changes to lower high ApoB or non HDL cholesterol ●      Why saturated fat, fiber, and gut health all influence your cholesterol numbers ●      Why blood pressure, not HRV, deserves more of your attention in perimenopause ●      How menopause hormone therapy really affects your cardiovascular risk ●      The minerals your heart needs to keep beating and pumping properly TIMESTAMPS 00:00 Heart Disease Risk in Women: ApoB, Lp(a), and the Tests Your Doctor Isn't Running 10:18 The Hidden Inflammation Driving Your Heart Disease Risk (And How to Test for It) 19:29 The Truth About Saturated Fat and Cholesterol After 40 22:19 The First Five Diet Changes to Lower High ApoB or Non HDL Cholesterol 29:24 Bloating, Gut Health and Thyroid: The Hidden Heart Disease Risks in Perimenopause 39:41 Why Stretching Might Be Protecting Your Arteries, Not Just Your Joints 51:48 Does Menopause Hormone Therapy Actually Protect Your Heart? VALUABLE RESOURCES • Take the BioSyncing Quiz to help you understand what's actually happening in your body — and how to fix it.

Europe's best founders are no longer building for Europe first and the US later. They're building global companies from day one.In this episode, Andreas Munk Holm speaks with Seedcamp Principal Will Bennett as Seedcamp announces a new $320 million fund, split between a $220 million Core fund and a $100 million Select fund.Will explains why Seedcamp is expanding its US presence, how its transatlantic bridge helps founders access customers, talent and capital earlier and why the firm's conviction remains centred on backing exceptional founders before the company or category is obvious.The conversation also explores how AI is intersecting with science and the physical world, what excites Seedcamp about the next generation of startups and how venture is evolving after nearly two decades of investing.Disclosure: EUVC is a small LP in Seedcamp's latest fund and has also invested in previous Seedcamp funds.Key highlightsWhy Europe's best founders are building global companies from day oneThe strategy behind Seedcamp's $320 million fund raiseHow the transatlantic bridge helps founders access customers, talent and capital earlierWhy Seedcamp backs founders before the company or category is obviousHow AI is intersecting with science and the physical worldTimestamps(00:00) Introduction and Seedcamp's $320 million fund raise(01:00) Why Seedcamp launched a dedicated Select fund(03:00) Supporting founders beyond the first cheque(05:00) Venture's next frontier(06:00) AI, science and the physical world(11:00) Valuations, competition and the current market(17:00) Why Seedcamp is building a transatlantic bridge(18:00) Helping European founders win in the US(19:00) Building global companies from day one(21:00) Why pre-seed investors should avoid rigid theses(24:00) Closing thoughtsSubscribe to EUVC, the home of European tech, for more insights.

Soos verwag het die Britse premier Keir Starmer vanoggend bedank. Dit kom na 'n leierskapstryd begin is toe Andy Burnham Donderdagaand die Makerfield-tussenverkiesing gewen het en dus, LP geword het wat hom in staat stel om Starmer se leierskap uit te daag. Starmer het die aankondiging buite 10 Downingstraat gemaak. Hy sê die vraag was of hy die Arbeidersparty tot die volgende verkiesing kan lei.

"Making the effort earlier totally changes the trajectory for the rest of your life,” says Jeremy London, MD. London is a board-certified cardiovascular surgeon with more than 25 years of clinical experience caring for patients across the full spectrum of heart disease — from prevention to advanced intervention. Dr. London received his medical degree from the Medical College of Georgia and completed his general surgery residency at Joseph's Hospital in Denver, Colorado. He completed a general vascular and thoracic surgical fellowship at the Carolinas Medical Center in Charlotte, N.C. To deepen his understanding of medicine, he completed the Institute of Functional Medicine core program. 00:00 - When a cardiac surgeon has a heart attack 10:46 - Waking up with different priorities 13:49 - Missed signals 18:35 - The CGM experiment that revealed pre-diabetes 21:43 - The 5 tests that actually matter 25:44 - Diving into Lp(a) 30:36 - Target numbers for primary prevention 32:26 - Why taking medication isn't failure 38:24 - Atherosclerosis starts in childhood 41:19 - Why a zero calcium score doesn't mean you're safe 45:40 - What we don't know 48:41 - GLP-1s & the future of prevention For more about London, visit his website: https://drjeremylondon.com/  We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Burning. Itching. Tearing during sex. Told it's "just dryness" or "just menopause" — but the treatment never works.It might be lichen sclerosus or lichen planus — two skin conditions that affect the vulva and are diagnosed late (often years late) because they get mistaken for recurrent yeast infections or normal aging.In this episode, I sit down with Dr. Jill Krapf of the Center for Vulvovaginal Disorders to talk about:

A lot of LP investors learned hard lessons over the last few years. In this episode, Travis Watts breaks down what really happened during the multifamily downturn and why so many deals struggled when interest rates changed faster than expected. Travis shares his experience as a full-time LP investor involved in roughly 30 deals across multiple asset classes. He explains why self-storage performed more resiliently, what surprised investors about floating-rate debt, and why LPs are asking much better questions today before investing in deals. Key topics and takeaways: Why interest rate cap renewals blindsided many operators How floating rate debt created pressure across multifamily portfolios Why self-storage held up better during the downturn What LP investors are paying attention to now Why multifamily recovery will likely be slow instead of a fast rebound How lower leverage and cleaner debt structures are changing new deals Guest Information: Travis Watts LinkedIn: Search “Travis Watts” on LinkedIn Call To Action: If you are an LP investor or interested in passive real estate investing, connect with Travis Watts on LinkedIn to continue the conversation.

On today's show, It's the debut of World Music Day & Bonnaroo, a blues legend passes away, and the LP debuts. For more music history, subscribe to my Spotify Channel or subscribe to the audio version of my music history podcasts, wherever you get your podcasts fromALL MUSIC HISTORY TODAY PODCAST NETWORK LINKS - https://allmylinks.com/musichistorytodayChapters: 00:00 Intro 00:34 What happened on this date in music history13:06 Music award ceremonies that were held on this date in music history19:02 Albums released on this date in music history 28:19 Singles released on this date in music history 31:27 Birthdays of music artists on this date in music history 45:00 Passings of music artists on this date in music history 53:22 What's on tomorrow's episode

Part 2 of my conversation with guest Jay Breitling as we count down our favorite music of 2026 so far. Show notes: Breitling's #6: Kurt Vile's love letter to Philly KV writes songs about nothing and they're great Kumar's #6: Great album from Chicago's Ratboys Leading the wave of bands with sweet female vocals and rocking instrumentation Breitling's #5: 17-track compilation from the Laughing Chimes It's like a typewriter, retro and satisfying Kumar's #5: Hot indie rock from Philly's Gladie Led by former singer of Cayetana Breitling's #4: First new LP from Broken Social Scene in a decade Reembracing the combustible Freakin' Fanelli Bootlegs became readily available in the early '00s Kumar's #4: Montreal post-punk trio with an excellent release Political lyrics Breitling's #3: The Notwist returns with a sound that combines their different phases Back to basics Documentary captures their weirdness Kumar's #3: Austin synth-punk weirdos Drakulas return with gloriously fun release Featuring members of the Riverboat Gamblers and Rise Against Breitling's and Kumar's #2: We did it! Courtney Barnett with a triumphant album recorded in California Sings about everyday issues in her life Breitling's and Kumar's #1: We did it again! Alex Edkins of METZ with his second Weird Nightmare album Not as dark and heavy as METZ, but exciting and exhilarating Very hooky and uplifting Looking forward to new stuff from Kiwi Jr., Strange Pains, Johnny Foreigner, Afghan Whigs, The Cramps (archival release), The Fall, Eddy Current Suppression Ring, Evil Island   Completely Conspicuous is available through Apple Podcasts. Subscribe and write a review! The opening and closing theme of Completely Conspicuous is "Theme to Big F'in Pants" by Jay Breitling. Voiceover work is courtesy of James Gralian.

You are not doing the heavy lifting alone anymore.If you are living with symptoms that seem confusing, inconsistent, or flat-out exhausting, we have a vital surprise for you. For years, the Lichen Sclerosus Support Network (LSSN) has been a dedicated sanctuary for the LS community. But we know that many of our brothers and sisters are also navigating the painful, isolating world of Lichen Planus (LP) without a clear place to call home. Today, that completely changes. LSSN is officially expanding our mission to build a dedicated resource home for Lichen Planus. Joining host Kathy to launch this new frontier is Dr. Erin Foster, a leading mucosal specialist from Oregon Health & Science University. Dr. Foster is stepping up as the head of our brand-new LP department to help turn scattered search spirals into hard clinical research, clearer tracking tools, and real community hope. Visit our new LP website at https://aboutlichenplanus.comWhat You Will Learn: Core Episode TakeawaysThe Blueprint of Lichen Planus: How this autoimmune response targets the deep T-cells of your body, and why it can show up across your skin, mouth, scalp, nails, esophagus, or genitals. The Diagnostic Blur (LS vs. LP): Why classic textbook definitions are outdated. Dr. Foster shares why hyperkeratotic LP can present as completely white patches on the vulva, mimicking lichen sclerosus perfectly and causing years of misdiagnosis. The 3-to-9 Month Medication Trigger Window: A look at how common everyday medications like Ibuprofen, Metformin, and Beta-blockers can set off a delayed immune flare-up months after your first dose. The Truth About Scarring: Why identifying symptoms early in areas like the scalp (LPP) or moist mucosal tissues is vital to halt irreversible tissue fusion and hair loss. The Systemic Escalation Ladder: A breakdown of how treatments look when topical steroid creams aren't enough, including safe pills like Hydroxychloroquine and immune modulators like Methotrexate. *Self-Advocacy & Educational Use Only. This podcast episode and its accompanying notes exist to organize personal observations, validate patient experiences, and support informed conversations with your care team. This content does not diagnose medical conditions, replace formal clinical examinations, or determine medication directives. LichenS Support Network does not provide clinical diagnoses or official treatment plans. Please coordinate directly with a qualified, licensed professional for all medical evaluations, physical tissue biopsies, and therapeutic care strategies.

In this special edition of The Gray Report, Griffin Haddad sits down with Blake Pieroni, Senior Manager of Capital Markets at Gray Capital, for a conversation about life behind the scenes of raising capital for multifamily real estate.Blake recently helped close a $22 million equity raise in just 11 days — the fastest in Gray Capital's history — all while adjusting to life with a newborn at home and chasing a sub-6-minute mile.In this episode, Griffin and Blake dig into:

When news broke in 1952 that Christine Jorgensen, an ex-GI from the Bronx, had undergone gender-affirming surgery, she became a global sensation. In this 1957 interview, meet the thoughtful woman behind the frenzied headlines as she took on the burden of educating the public about trans people. Visit our ⁠episode webpage⁠ for background information, archival photos, and other resources, as well as a transcript of the episode. ——— Audio source: Christine Jorgensen Reveals, an LP recording of a 1957 interview between Christine Jorgensen and Nipsey Russell (credited as R. Russell), released in 1958 by J Records, New York, NY. ——— To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

MGH is back for another dive into the archives! Drawing from Eric's own collection of rare interviews and other repositories of LGBTQ history, we'll bring you the voices of seven LGBTQ change-makers and allies whose stories will take you from 1920s Harlem to the halls of power in 1980s D.C.  ——— Audio sources: - Christine Jorgensen Reveals, an LP recording of a 1957 interview between Christine Jorgensen and Nipsey Russell (credited as R. Russell), released in 1958 by J Records, New York, NY. - Mabel Hampton Oral History Collection, used by permission of the Lesbian Herstory Archives. - Barney Frank interview via the Making Gay History archive. - "Lou Sullivan and Dr. Ira Pauly Interview, Part 1," January 1988, GLBT Historical Society Film & Video Collection, courtesy of the GLBT Historical Society. ——— To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Free course: Improve your metabolic healthGet our free email course on how glucose, nutrition, exercise, sleep, and measurement can help you build habits that support better energy and long-term health: ⁠⁠⁠https://levels.link/wnl⁠High cholesterol. Elevated ApoB. A positive CAC score. Now what?Most people quickly find themselves trapped between two extremes: simplistic advice to “cut saturated fat” and online influencers insisting cholesterol doesn't matter at all.In this episode of A Whole New Level, Mike Haney sits down with clinical research scientist Dr. Kevin Maki to cut through the confusion.Drawing on more than 35 years of cardiovascular research, Maki explains why heart disease risk is about much more than LDL cholesterol alone. He breaks down the roles of inflammation, blood sugar, family history, kidney function, and lipoproteins, while also making a clear case for something many people resist: LDL and ApoB still matter. A lot.The evidence increasingly suggests that when it comes to atherosclerosis, lower for longer is better. That has important implications for diet, statins, and how early we should intervene.Mike and Dr. Maki also tackle saturated fat, seed oils, red meat, industry-funded research, and how to separate evidence from online nutrition debates.

We've all been there. You're sitting across from someone you hope will hire you, there's the potential for real money, and they ask you to do what they think is just a little bit of work on spec for free. Not to mention they want you to submit a proposal before they commit.You might have said okay and done that work, submitted that proposal, and crossed your fingers. Maybe you booked that client in the end, maybe you didn't. But you probably didn't feel great about it either way.This just happened to one of the students in the current No BS Mastery cohort. The difference was that not only did she hold her boundary of not working for free, but she also had a clear way to follow up by sending them the link to her LP. People talk about boundaries like they're a mindset problem. You just have to believe in yourself and you'll stop doing work for free and charging what you're worth. But I don't think that's really how it works. I think boundaries have a lot more to do with structure. Because when you have the right structure, boundaries are really easy to hold.All this month, I've been sharing some of the more unexpected wins coming out of the new No BS Mastery cohort, and today I want to talk about why the No BS Model is making it so much easier for my students to confidently maintain their boundaries and say no to free work and clients who aren't a good fit.Tune into this episode to hear:How clear processes and structure make it so much easier to maintain your boundariesHow the LP process helps you say no to free work without closing the door on the relationshipWhy it's so necessary to filter out tire kickers and bad fit clients, even when you're not fully bookedWhy just five weeks in, my students have already made incredible strides in their confidenceResources:Watch my TED Talk: When You Bank True Confidence, Anything Is PossibleGrab the first chapter of my new book Scale Solo: scalesolobook.comProgram: No BS Mastery: https://nobsmastery.com/programThe Price to Freedom Calculator™ - http://nobsmastery.com/priceGrab a copy of my book: Badass Your Brand - https://www.badassyourbrand.com/Program: No BS Agency Mastery: https://join.nobsmastery.com/agency-masteryNo BS Clients Lab: https://nobsclientslab.com/

In the final installment of “The Shadows Behind the Shadows” series, which examines the literary, cinematic, theatrical, and other inspirations for Dark Shadows storylines, I look at the final story arcs of the series – 1995, the Summer of 1970 (aka the Ghosts of Daphne and Gerard), 1840, and 1841 Parallel Time. Influences on Night of Dark Shadows are also touched upon. The end of the episode features messages and posts from a variety of listeners who shed light on additional sources. Terror at Collinwood and Shilling Shockers shirts, stickers, mugs, and merch at the Penny Dreadful XIII TeePublic shopHelp support the podcast by donating at Buy Me a CoffeeFollow the Terror at Collinwood Facebook pageDark Shadows 60th Anniversary Celebration Jul. 31-Aug. 2, 2026 – INFOUCLA 60th Anniversary Dark Shadows screening event INFO Dark Shadows Noir pre-order at Hermes PressResident of Collinwood podcast: “Bringing a Mummy to Dark Shadows”The Back Room at the Blue Whale podcast Episode 6Montague Summers, Occultist: A Study of the Writings on Witches, Vampires and Werewolves from McFarland BooksHermes Press Dark Shadows books linkDark Shadows 60th Anniversary Edition 2 LP record set pre-order LINKThe Curious Characters of 1897 Collinwood on AmazonWoman's World article on Kate Jackosn by Ed Gross LINKThe Articulate Coven Anne Rice's Immortal Universe podcastDark Shadows Wiki linkDark Shadows News Page on FacebookGeorge Kalogridis YouTube Channel (DS AI animations)Surfing the Shadows surf rock cover of Robert Cobert's Dark Shadows theme by Johnny D & The MoonlightersTaC logos by Eric MarshallPenny Dreadful's Shilling Shockers on Etsy

A FEDERAL GRAND JURY JUST INDICTED THE SOUTHERN POVERTY LAW CENTER FOR ALLEGEDLY PAYING NEO-NAZIS TO STAY NAZIS. Today we walk through the New York Post bombshell on the SPLC indictment, the alleged $3 million pipeline through shell companies to violent extremists, and the wider pattern of manufactured hate stories that have shaped American media for forty years. Then we head to California, where Arnold Schwarzenegger just blew the whistle on Sacramento's gas price racket, and Adam Smith's 250-year-old playbook explains exactly why Californians are paying nearly six bucks a gallon. Judge Andrew Napolitano joins us with his sharp new column asking whether America at 250 is still a republic or already an empire. Then we simulcast with Chris Salcedo on the future of the liberty movement, the collapse of the LP, and whether there's still room for a liberty wing inside conservatism.

We are quickly approaching the third anniversary of the death of Renata Scotto, and that sad commemoration, combined with my desire to produce an episode celebrating Opera Queens, prompted this episode, which features a rare live LP that I once owned a few decades ago and recently returned to my collection. It features live performances of “our diva” from the stage of Carnegie Hall on two different occasions in the mid- to late-1970s: the first, a gala concert on September 12, 1975 with Eve Queler leading the Opera Orchestra of New York on which Scotto performed Rossini (the bravura rondo from Armida) and Donizetti (the mad scene from Anna Bolena). She also sang “Tu che invoco” from Spontini's La Vestale on that concert, and though it was not included on that record, I have unearthed a live recording of that exact performance, which is also included on the episode. The second concert featured on that LP took place on October 31, 1979 under the baton of Lorin Maazel leading the Cleveland Orchestra, and includes a rare performance of Scotto singing from Cherubini's Medea as well as the mad scene from Bellini's Il pirata. In all of these, Scotto is in sterling vocal form, which allows her to fully explore the expressive bel canto possibilities of this music. Since Scotto was also widely accused of being anti-Callas, I also dispute that view with some comments that Scotto made in an interview about Callas's importance as the high priestess of bel canto. I also intone a few more nasty reviews and comments from those who do not hold Scotto in the same high esteem that I (we!) do. For I, too, am one of those opera queens that we are celebrating today. I just happen to have better taste than those that are dissing our diva! Countermelody is the podcast devoted to the glory and the power of the human voice raised in song. Singer and vocal aficionado Daniel Gundlach explores great singers of the past and present focusing in particular on those who are less well-remembered today than they should be. Daniel's lifetime in music as a professional countertenor, pianist, vocal coach, voice teacher, and author yields an exciting array of anecdotes, impressions, and “inside stories.” At Countermelody's core is the celebration of great singers of all stripes, their instruments, and the connection they make to the words they sing. By clicking on the following link (https://linktr.ee/CountermelodyPodcast) you can find the dedicated Countermelody website which contains additional content including artist photos and episode setlists. The link will also take you to Countermelody's Patreon page, where you can pledge your monthly or yearly support at whatever level you can afford.

Dan Teran is the co-founder Gutter Capital, a concentrated seed fund in NYC, and Elbow Grease, the accelerator that puts 15 startups in one building and helps build their teams for them.Gutter just announced a $75M Fund III and opened applications for the second Elbow Grease batch (apply below by July 31st)We get into starting an accelerator when there's already a hundred of them, why Gutter prefers very concentrated portfolios, what it was actually like selling Managed by Q to WeWork, why raising a fund turned out to be harder than selling a company, why he thinks startups should form a board and use OKR's from day one, and the time he went big-wave surfing with Adam Neumann and Laird Hamilton.Thank you to James Gettinger, Satya Patel, Abhinav Kapur, and JT White for help brainstorming topics for the conversation.Thank you to Numeral, Flex, Amplitude, and Merge for supporting this episode.Numeral: The end-to-end platform for sales tax and compliance https://www.numeral.comFlex: Get premium banking and a net 60 day credit card at 0% APY https://home.flex.one/referral/bananacapitalAmplitude: AI analytics, all you have to do is ask https://www.amplitude.comMerge: Every modal. One API. Total control. Check out Merge's Agent Handler. merge.dev/turnerTimestamps:(0:00) Elbow Grease: NYC's new accelerator(7:39) Building a small, hands-on, in-person experience(13:39) Recruiting 100 people into portfolio companies(16:25) Portfolio concentration makes investors more helpful(24:58) Why raising Fund 1 was so hard(28:08) Advice for new fund managers(30:30) “Hiring today is as competitive as ever”(32:23) Selling Managed By Q to WeWork(35:23) “Never raise too much money”(39:43) Almost buying his company back from WeWork in Feb 2020(43:50) Starting Gutter Capital in the depths of COVID(49:34) Funding angel investing with gambling proceeds(52:39) Behind the name “Gutter Capital”(54:49) “Raising a fund is like getting punched in the face”(59:03) Writing long LP letters(1:06:45) Investing in real world problems(1:09:48) What a Gutter founder looks like(1:12:46) How Gutter makes new investments(1:18:41) Importance of customer calls at pre-seed(1:21:59) Evolution of NYC tech over last 15 years(1:26:15) Why you should form a board at Seed(1:28:29) How to run a Seed stage board meeting(1:34:04) Sharing carry with portfolio founders(1:35:56) The best founders need lots of help(1:39:30) Big wave surfing with Adam Neumann and Laird HamiltonReferencedApply to Elbow Grease: https://forms.gutter.cc/eg0002-applicationElbow Grease: https://elbowgrease.cc/Gutter Capital: https://www.gutter.cc/WeWork Acquires Managed By Q: https://techcrunch.com/2019/04/03/wework-acquires-managed-by-q/Follow DanLinkedIn: https://www.linkedin.com/in/danteran/Follow TurnerTwitter: https://twitter.com/TurnerNovakLinkedIn: https://www.linkedin.com/in/turnernovakSubscribe to my newsletter to get every episode + the transcript in your inbox every week: https://www.thespl.it/

Europe's challenge isn't a lack of entrepreneurs. It's making sure enough capital reaches them.In this episode, David Cruz e Silva speaks with Jaap Vriesendorp, Managing Partner at Marktlink Capital, one of Europe's most active LPs in venture capital, about why backing European innovation matters, how to build a resilient venture portfolio and what separates the best fund managers from the rest.Jaap shares the thinking behind Marktlink's venture strategy, from vintage diversification and secondaries to manager selection and portfolio construction. He also explains why scale matters in private markets, how the firm uses data science and AI in its investment process and why many LPs make the mistake of running out of capital for their best-performing managers.The conversation also covers emerging managers, long-term capital formation and why Europe deserves more credit as a venture ecosystem.Key highlights:Why European entrepreneurs should back European entrepreneursHow one of Europe's most active VC LPs approaches venture investingThe role of primaries, secondaries and vintage diversificationWhat Jaap looks for in emerging managersWhy scale matters in private marketsHow data science and AI support investment decisionsThe biggest mistakes fund-of-funds investors makeWhy long-term capital is critical to venture successTimestamps:(00:00) Why Europe needs more capital flowing into innovation(02:00) Introduction and Jaap Vriesendorp's background(05:00) From McKinsey to launching a venture fund-of-funds(08:00) The merger that created Marktlink Capital(10:00) Building a platform backed by entrepreneurs(14:00) Why scale matters in private markets(17:00) Product strategy across venture, private equity, co-investments and private credit(23:00) How Marktlink uses data science and AI in investing(29:00) Marktlink's venture investment strategy(30:00) Vintage diversification, primaries and secondaries(33:00) Why annual funds help secure long-term LP capital(37:00) What Marktlink looks for in emerging venture managers(40:00) Why Europe deserves more credit as a venture ecosystemFurther listening:⁠⁠⁠E347: The $26B CIO Who Turned Superforecasting Into Alpha - How I Invest with David Weisburd⁠⁠⁠Learn more about the Love Tomorrow Summit and the programmes EUVC is curating, and secure your tickets ⁠⁠here⁠⁠.

Implementing a new habit rarely feels life-changing at first. Going for a morning walk and getting a few minutes of sunlight, or visualizing checking something off a to-do list, might sound like activities that barely move the needle. Yet over time, those small actions often become the difference between feeling stuck and becoming the person you're capable of being. And after reading the first chapter of Jon Gordon's newest book, The Power of Positive Habits, I felt the benefits from that one simple action in the first 5 minutes. Jon is the bestselling author of 33 books, including The Energy Bus, which has sold more than 3.5 million copies worldwide. But before becoming one of the most respected voices in leadership and personal development, Jon struggled with negativity to the point that his wife told him their marriage wouldn't survive unless he changed. That wake-up call led him on a journey that transformed his mindset, career, and life. In our conversation, Jon shares the habits that reduce friction and make it easier to follow through, why becoming your own greatest encourager can change everything, and how letting go of the past can unlock the mental blocks that prevent you from becoming the best version of yourself. KEY TAKEAWAYS Why Jon Wrote The Power Of Positive Habits The Morning Habit That Changed Everything The Habit Before The Habit Using Visualization To Follow Through Become Your Own Greatest Encourager Learn From Everyone: The Habit & Mindset Forgive Fast And Start Growing Don't Let Old Battles Block New Victories Don't Let Good Get In The Way Of Great  The Beginning of Success for the Savannah Bananas How Reading Jon's Book Will Payoff On The First Day How You Can Learn More with Jon Gordon Get The Full Show Notes To get full access to today's show notes, including audio, transcript, and links to all the resources mentioned, visit MiracleMorning.com/641 Subscribe, Rate & Review I would love if you could subscribe to the podcast and leave an honest rating & review. This will encourage other people to listen and allow us to grow as a community. The bigger we get as a community, the bigger the impact we can have on the world. To subscribe, rate, and review the podcast on iTunes, visit HalElrod.com/iTunes. Get Access to Hal's Books and the Miracle Morning App For access to Hal's Miracle Morning books, CLICK HERE.  To upgrade your morning routine, CLICK HERE to download the Miracle Morning App.  Book Hal to Speak At Your Event! If you'd like to book Hal to speak at your next event, CLICK HERE. Connect with Hal Elrod Facebook Twitter Instagram LinkedIn YouTube TikTok   Copyright © 2026 Miracle Morning, LP and International Literary Properties LLC  

Send us Fan MailIn this episode we are bringing you a Shorty…an episode with just 2 books, and we hope it might be just what you need!  Our short stack is tied together with the common theme of being Homework we assigned to one another.  We hope you'll give us an A+/100%!Featured Books:The Victory Garden by Rhys Bowen (LH to LP)The Choice by Nora Roberts (#3) (LP to LH)Additional Books That Go Along with Our Stack:The Tuscan Child by Rhys BowenThe Paris Assignment by Rhys BowenThe Awakening by Nora RobertsThe Becoming by Nora Roberts‘In Death' series by JD Robb (Nora Roberts)Ways to contact us:Join us on Patreon for extra content: https://www.patreon.com/c/BookBumblePodcastFollow us on Instagram - @thebookbumbleFacebook:  Book BumbleOur website:  https://thebookbumble.buzzsprout.comEmail:  bookbumblepodcast@gmail.comSupport the showIf you like our podcast please help us: Rate and review us, subscribe, follow us on Insta, and join our Team Patreon!  It won't be the same without you!

What does it look like when one of the world's most longstanding institutional investors ($120B) decides to go deeper into venture capital? And what happens when one of the most respected LP teams in the business joins forces with them?Thomas Kristensen, who is responsible for the venture capital business at LGT Capital Partners, joins hosts Nick and Beezer for a wide-ranging conversation that doubles as an announcement: the Sapphire Partners team – including Beezer, Laura and Nate – have joined LGT Capital Partners. Thomas explains why the fit made sense.LGT Capital Partners manages over $120 billion on behalf of more than 700 institutional clients and is owned by the Princely Family of Liechtenstein. That ownership brings a long-term perspective, often measured in decades rather than years, and it shapes how Thomas and his team approach venture: with patience, close partnership and a willingness to be both buyer and seller in private markets.Together with Nick and Beezer, Thomas unpacks the firm's recently published white paper on the case for increasing venture allocation, built on three pillars: lifecycle diversification, an innovation hedge against AI-driven displacement and the maturation of secondary markets as a liquidity tool. He also offers a frank assessment of the current market, noting that the pace of deployment feels reminiscent of 2020-2021, and that a valuation dip may be coming regardless of how transformative AI ultimately proves to be.From the endowment model's stress test to the temptation of clinging to a single fund-returner, this is a thoughtful conversation about long-term thinking from an investor who has spent more than two decades refining his approach.Quotes“It's not new that incumbents are challenged by new entrants. I think what's new is the speed at which this is happening. In the age of AI, it feels like there is a risk that many incumbents could be displaced quite quickly. And so including venture capital in your portfolio is a way of hedging against this.”“Are LPs gonna run out of capital? I don't know. Sometimes I wonder if the world is going to run out of capital to fund CapEx for AI right now. We always say, ‘Listen, if you come into venture capital as an asset class, if you're an allocator, you can go in when it's hot, you can go in when it's not. You will only really figure out in hindsight.' The most important thing if you start committing to venture is, make sure that you can commit at a steady pace over a long, long period of time because it's a market you cannot time. There's just no way.”Time Stamps04:13 Meet Thomas Kristensen, Head of Venture Capital at LGT Capital Partners05:52 The Princely Family of Liechtenstein and the Long-Term Mindset08:37 The White Paper: Why LGT Capital Partners Is Increasing Its Venture Allocation09:45 Three Pillars: Lifecycle Diversification, Innovation Hedge, and Secondary Markets12:35 Big News: The Sapphire Partners Team Joins LGT Capital Partners17:35 LP Consolidation: What It Means for GPs23:47 GP Advice: Keep First Things First on LP Alignment32:03 Engineering a More Liquid Private Portfolio37:07 AI Market Heat and Fundraising Pace45:44 Closing Remarks and What's NextLinksConnect with the guest and hosts on LinkedIn!• Thomas Kristensen• Beezer Clarkson• Nick ChirlsLearn more about:• LGT Capital Partners• Asylum Ventures• OpenLP• LGT Venture Capital White Paper

The last time James checked in with OK Cool, it was during the pandemic, and they were just faces on a screen. Now, they finally meet in vivid 3D at HIDE+SEEK on Randolph Street ahead of the band's Sunday performance at the 29th annual Taste of Randolph! Haley and Bridget reflect on their creative output since 2021, including the release of two EPs (Surrealist and Fawn) and their 2025 full-length LP, Chitchat. They also break down the meaning behind the catchy, residency-taking track "Jeans," reveal the Borat movie quote behind their "Wawwoowewa" music video, and share the exciting news that they have officially started tracking their next record. Special Thanks to Our Sponsor Exploding House Printing is here for all of your screen printing, embroidery, and other merchandising needs. Check out their work on Instagram at @explodinghouse, or check out their site at explodinghouseprinting.com for a quote, or to see a list of some of their clients.  

Matthew "Oki" O'Connor is the CEO of Scientific Affairs at Cyclarity Therapeutics, a clinical-stage biotech building a new class of medicines designed not to slow the accumulation of vascular damage but to reverse it. Oki and Chris first crossed paths as postdocs at Lawrence Berkeley National Lab in the mid-2000s — Oki was in Irina Conboy's lab, not far from the late Judy Campisi's group, where Chris was then working on cellular senescence. After Berkeley, Oki spent nearly a decade running the research program at the SENS Research Foundation, the organization most identified with the "damage repair" framing of aging biology, before co-founding Cyclarity (then known as Underdog Pharmaceuticals) in 2019 to translate one of SENS's most drug-tractable ideas into an actual molecule.When Oki was last on the show in March of 2023 (Episode 36), Cyclarity was deep in IND-enabling work and its lead asset, UDP-003, had only ever seen the inside of a mouse artery. At the end of that conversation, Chris asked what Oki hoped to be discussing the next time he visited. He answered, bluntly, that he wanted to be presenting human data. Last month, at the AHA Vascular Discovery Sessions, Cyclarity reported the results of their first-in-human Phase 1 trial of UDP-003 — a designed cyclodextrin that selectively binds 7-ketocholesterol, the oxidized cholesterol species that drives foam cell formation and arterial plaque. He's back to discuss what the drug actually did when it went hunting for 7KC inside a living human being.In this episode, Chris and Oki cover the unmet need that lipid-lowering drugs — statins, PCSK9 inhibitors, the coming Lp(a) agents — still don't address: none of them remove the damage already sitting in an artery wall. Oki explains the basic chemistry of 7-ketocholesterol and why macrophages, lacking the machinery to recycle it, collapse into foam cells and seed the necrotic core of advanced plaque. They walk through the engineering of UDP-003 as a dimeric beta-cyclodextrin "double cone" tuned for a single oxidized cholesterol species, the design of the 72-volunteer Australian Phase 1, and the exploratory pharmacodynamic readout that has the field's attention: dose-dependent urinary excretion of 7KC, stoichiometric with drug, cleared within a day. The conversation then turns to the 150-patient Phase 2 plan in coronary artery disease patients with plaque imaging as the primary biological readout, the funding math that stands between Cyclarity and that trial, the platform's reach into NASH, vascular dementia, AMD, and aging itself, and how all of this descends from the SENS damage-repair philosophy that Oki has been carrying since LBL.The Finer Details:- Why current standard of care is not enough — statins, PCSK9 inhibitors, GLP-1s, and the soon-to-arrive Lp(a) lowering agents all act by slowing the accumulation of arterial damage, not by reversing what's already there; despite 30 years on the market, statins have never demonstrated an all-cause mortality benefit in a clinical trial, and even the best statin imaging data shows only 1–2% plaque volume regression at very high doses in a subset of patients- The scale of the problem — atherosclerosis is estimated to contribute to roughly 40% of all human deaths once heart attack, stroke, and a surprisingly large COPD contribution are risk-adjusted in, on top of an enormous morbidity tail that includes angina, peripheral artery disease (up to and including amputation), and a growing case for vascular dementia as an undercounted driver of cognitive decline- The biology of 7-ketocholesterol — when an oxygen free radical reacts with cholesterol, it preferentially attacks the 7 position, and a second oxidation step locks the molecule into 7KC, a stable toxic species cells were essentially never equipped to recycle; it builds up in long-lived cells like macrophages, eventually shutting down their ability to traffic lipids back to the liver via HDL and converting them into foam cells that seed soft plaque and, over years, the necrotic core of advanced lesions- The molecular design of UDP-003 — cyclodextrins are naturally occurring carbohydrate rings; the beta size fits half a cholesterol molecule, and Cyclarity's in silico work showed that two beta-cyclodextrins facing wide-side to wide-side form a "double cone" that can fully encapsulate a single cholesterol; engineered correctly, that wrapper can be made selective for 7KC over native membrane cholesterol, which is what gives the drug its therapeutic window- The Phase 1 trial design and result — a traditional 72-volunteer safety study in Australia, split between single ascending dose and multiple ascending dose arms, escalating up to six doses at what Cyclarity believes will be the efficacious level; no serious adverse events, no bioaccumulation, drug excreted essentially completely in the urine (as predicted preclinically), and — the headline exploratory endpoint — dose-dependent urinary 7-ketocholesterol appearing on the same timescale as the drug, consistent with one molecule of UDP-003 binding one molecule of 7KC and leaving the body together- What the urinary 7KC readout can and cannot tell you — the easiest 7KC to mobilize is the free pool in circulation, but there is not nearly enough of it floating in the bloodstream to account for what came out in urine, which means the drug is reaching deeper compartments; how much is coming from vessel wall plaque versus liver versus other peripheral tissues will require the imaging endpoints of Phase 2 to answer- The Phase 2 plan — 150 coronary artery disease patients (the coronary being, as Oki puts it, the artery most likely to kill you), with baseline plaque imaging, a year of dosing, and a repeat scan; safety and PK continue, inflammatory biomarkers come on, and plaque volume change is the prize — for context, a 1% change in plaque volume is associated with roughly a 20% change in next-year risk of heart attack or stroke- The funding math and the platform — Cyclarity has raised $33M to date and needs roughly $45M more to run the Phase 2, with Phase 3 cardiovascular outcomes trials running into the hundreds of millions and likely requiring a pharma partner; beyond atherosclerosis, 7KC is elevated in NASH livers, in Alzheimer's brains, and in the retinal cells that die in age-related macular degeneration, and the underlying chemistry — designed binders that drag a specific toxic molecule out of the body — is meant to generalize into a pipeline against other accumulated damage species, the direct intellectual descendant of the SENS damage-repair programQuotes:"Atherosclerosis, or the plaque that builds up in your blood vessels in your arteries, is estimated to cause approximately 40% of all human death.""When [the macrophage] eats up too much oxidized cholesterol, it just accumulates it… And that's when you get this transition to these kind of monster blob cells called foam cells.""One molecule of our drug is supposed to bind one molecule of 7-ketocholesterol and then go away and never be seen again. You excrete both of them together.""A 1% change in plaque volume is associated with a 20% risk in the next year of your probability of having a heart attack or a stroke.""You pick one target at a time, you do it well, and you take it all the way to the clinic and hopefully prove that you can actually cure patients, help them get better, help their plaque shrink away, and prove that this approach can work."Links:Cyclarity Therapeutics: https://cyclarity.com

"Round the back for the old cherry brandy!"Recorded in New York on 6 August 1963, this satirical comedy album brought together Peter Sellers, Anthony Newley, Joan Collins, Leslie Bricusse, Daniel Massey and Michael Lipton at the height of the Profumo Affair.The midnight session accommodated Newley and Massey, whose Broadway shows had only just finished. The idea had been conceived less than two weeks earlier while Newley and Bricusse were holidaying in Montauk and they were keen to capitalise on Britain's appetite for political satire.The recording became a celebrity gathering, attracting around 100 guests including Vivien Leigh, Sammy Davis Jr., Roddy McDowall and Peter Lawford. By 2am, according to one witness, Sellers and Newley were sharing Scotch from a thermos while cigarette smoke filled the studio. The entire session was completed in just three hours.They rushed to release the album before public interest in the Profumo scandal faded but some record labels - notably Decca - were sniffy about its content, with mockery of the Royal Family a particular point of contention. Sellers responded: "Only a prude could possibly be offended by it."The BBC banned it from radio play, although excerpts had appeared on television. Contemporary reviews ranged from praise to outrage, reflecting the record's deliberately provocative humour. The album remains a fascinating snapshot of Britain's early-1960s satire boom, when comedians and performers increasingly challenged the deference traditionally shown to politicians, celebrities and public institutions.Joining Tyler to talk through the LP is Brett Tremble, who can be found on Bluesky @agnes-guano.bsky.social

This week we talk about LDL, HDL, and cardiovascular issues.We also discuss one-time therapies, statins, and pharmaceutical economics.Recommended Book: Blood by Dr. Jen GunterTranscriptCholesterol is the most common type of what's called a sterol, which is a type of steroid, but also structurally technically an alcohol. But functionally, and classified by scientists, cholesterol is a lipid, which in this case is similar to a fat in all but how the body uses it. Cholesterol is the type of sterol most commonly found in animals—other types are found in plants and fungi—and its function, and this is where it varies from fats, which are used to store energy, is to basically help hold the cell membrane together, and it also serves as an intracellular messenger.Cholesterol is especially prevalent in the brain and spinal cord of animals, but it's found throughout their bodily tissues, as well, and again, it's vital for holding everything together and helping things communicate, in addition to being a precursor for vitamin D, steroid hormones, and bile.You want to have cholesterol, then, as without it you would be dead.Too much cholesterol in the blood, however, can also make you dead, especially when it's bound to what's called low-density lipoprotein, or LDL, as that contributes to cardiovascular disease like heart attacks and aneurysms, which can massively impact one's overall wellness and quality of life, and at extremes lead to the whole system shutting down as a consequence of heart attack, stroke, and the like.A lot of things can contribute to the development of cardiovascular disease, including habits like smoking, genetic predisposition, and the enthusiastic consumption of alcohol and unhealthy foods. But high blood cholesterol, of the LDL variety, is one of the top contributors, as these low-density clusters of lipoprotein can clog the pathways that blood takes throughout our bodies. Other, denser types of lipoproteins, HDLs, can clear it, like a heavier, denser substance pushing through clogs of less-dense materials that are gumming up a pipe, but LDL is at times accumulated as a result of consuming delicious but unhealthy foods, which are hard to avoid, and for some people the only consistently available and affordable foods; and for other people LDL accumulates as a result of their genetic predispositions—two things that are devilishly difficult to change.What I'd like to talk about today is a new type of therapy that may be very good news for people who struggle with the accumulation of LDL, and why this is being seen as very good news more broadly, at the scale of entire nations, as well.—Pharmaceutical company Eli Lilly is testing a new, experimental drug called VERVE-102 which is a one-time infusion that is currently administered over the course of about four hours, and once completed, it turns off a gene called PCSK9, which is responsible for making a protein that regulates cholesterol levels in humans.As I said, this drug is still being tested, so these are early results. But in a study of 35 people with high cholesterol levels, high levels of LDL or LDL-C, which is short for lipoprotein cholesterol, they found that this infusion, which again, is a one-time treatment, so get it once and then theoretically at least you never have to get anything done ever again, it reduced those LDL and LDL-C levels by as much as 62%, and that reduction was maintained a year and a half after the infusion; that's how far out they're retested so far, and the hope is that each retest will continue to show the same.On the strength of those very promising results, a Phase 2 study has been planned by the end of 2026, and the US Food and Drug Administration, the FDA, previously fast-tracked this existing study, because of the promise and potential this drug already demonstrated in early studies; all of which is considered to be very significant progress and possibility.To understand that significance, though, it's useful to know some health stats. And I'm going to focus on the US here, as that's where this drug is being developed, but many wealthy countries have similar stats, at least in terms of cardiovascular disease struggles.As of 2024, which is the last year we had good, cohesive data on this in the US, it was estimated that about 11-12% of the US adult population has high cholesterol levels. This typically doesn't come with any symptoms, but it can contribute a higher risk for all those cardiovascular diseases, including heart attack and stroke. A further 86 million US adults have borderline or elevated cholesterol levels, which can easily tip higher, but also, even in that existing, elevated state, contribute to negative cardiovascular outcomes.There are treatments for high cholesterol, the most common of category of which are called statins, which reduce the production of LDL by inhibiting an enzyme that produces cholesterol in the body.Unfortunately, these drugs do come with some usually minor side effects, which can cause patients to stop using them, and they have to be taken daily, ideally at the same time each day. That necessity for consistency leads to a lot of incorrect or incomplete usage, which reduces the effectiveness of these drugs. But it's also estimated that only about 54.5% of US adults who would benefit from statins are currently taking one—so that's people who could benefit and who have it prescribed, and then within that number are all the people who are taking this drug incorrectly or incompletely, reducing the effectiveness. So a relatively small number of people who should probably be on these things are getting the full benefit they offer because of the nature of the drug.And that's not great, because in the US alone, heart disease is the leading cause of death for pretty much every adult demographic; men, women, people of most racial and ethnic and economic groups, you name it, heart disease is the biggest threat to their lives.One US citizen dies every 34 seconds of some kind of cardiovascular condition, and as of 2023, 1 in every 3 deaths in the US was caused by the same, adding up to just over 919,000 people that year.Between 2021 and 2022, alone, the cost of services and medications related to heart disease added up to more than $168 billion; again, that's just in that period, and just in the US.And once more, these are ailments that are caused or heavily influenced by high levels of cholesterol, which are themselves amplified by common lifestyle choices, environmental factors that are hard for many people to avoid, and just by raw, dumb luck because of genetics.This treatment category, then, is being seen as a pretty big deal because a one-time infusion means those who receive it don't have to remember to take a pill every day at the same time, and won't experience those statin-based side-effects.It also means that people who are currently costing the medical system a bunch of money each year, because they need treatments for all the issues they suffer as a result of high cholesterol, will suddenly cost the system a lot less money, for treatments and medications. Not for nothing, their health and quality of life will likely improve as well. So in addition to having better, healthier outcomes personally, their cost to healthcare systems will drop.Eli Lilly's drug isn't the only one currently working its way through clinical trials, either.Amgen is working on a similar treatment, and Novartis and Ionis Pharmaceuticals have drugs that are even further along in the process, their medicines that cut heart attacks, strokes, and cardiovascular deaths could be approved by the FDA as soon as next year.There are a lot of caveats worth noting here, including that the science is still out as to whether this approach, silencing proteins that lead to the creation of more LDL and a similar substance called Lp(a)—which is more dangerous because it's stickier and thus more likely to get stuck in important blood pathways, and it's also more likely to be caused by genetics than lifestyle—the word is still out on whether reducing these things in the body actually reduces hearth attacks and stroke.Some people have had this particular risk variable dramatically reduced, but have still suffered from cardiovascular events, which raises the question of whether this path is the right one to take in trying to reduce this category of health issues; the correlation between LDL and heart attacks and strokes might not be a clear-cut as long assumed.There's also the issue of price. Drug-makers are economically incentivized to sell treatments over cures, because that means they can continue selling their product over time, potentially for the life of the patient, and a cure, in contrast, is a one-time hit that in theory should alleviate the need for future treatment.There's a chance, then, that the drug-makers will decide they need to make these one-hit treatments really, really expensive in order to make their R&D dollars back and to make the kinds of profits their investors expect from them. That could then reduce the potential audience for these treatments, even if they are effective, and could further slow their deployment and future research in this space.If these trials continue to go well, though, there's a good chance that this combination of similar but distinct treatment types will provide a more sustainable alternative to current options, and that, like the recent bogglingly rapid and widespread deployment of GLP-1 treatments for all sorts of issues, could lead to a new paradigm in this facet of the medical world.Show Noteshttps://en.wikipedia.org/wiki/Cholesterolhttps://en.wikipedia.org/wiki/Cardiovascular_diseasehttps://en.wikipedia.org/wiki/High_cholesterolhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10982736/https://www.cdc.gov/heart-disease/data-research/facts-stats/index.htmlhttps://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1https://www.ama-assn.org/public-health/chronic-diseases/what-doctors-want-patients-know-about-high-cholesterolhttps://en.wikipedia.org/wiki/Statinhttps://pubmed.ncbi.nlm.nih.gov/42187087/https://abcnews.com/GMA/Wellness/new-drug-game-changer-people-high-cholesterol/story This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit letsknowthings.substack.com/subscribe

In this LP Deal Review, Chris Lopez is joined by Adam Cranmer and Christy Burakovsky to evaluate CL Fund III from Central Lending, a private credit fund focused on short-term residential real estate loans for fix-and-flip, ground-up construction, and small-balance investor projects. Andrew Boccia and Heather Dreves walk through Central Lending's lending model, portfolio composition, underwriting process, use of leverage, investor share classes, and how the fund sits between traditional fixed-income strategies and higher-upside real estate syndications. The conversation gets into why Central Lending focuses on smaller loan sizes, how it uses third-party valuations, what it tracks across borrower experience and credit quality, and why fraud detection has become a major part of private credit underwriting. The LP panel then digs into the questions passive investors should be asking before investing in a debt fund: how loans are valued, what happens when a borrower defaults, how draw management can reveal problems before maturity, whether loan tapes and audited financials are available, how leverage impacts returns and risk, and what investors should understand about redemptions. For LPs evaluating private credit, this episode offers a practical look at what sits behind headline yield: underwriting discipline, loan-level monitoring, loss mitigation, liquidity management, and alignment between the fund manager and investors. Key Takeaways How Central Lending underwrites private credit deals across current cost, collateral value, final cost, and after-repair value Why borrower experience, draw activity, and communication can be early indicators of loan performance How the fund uses third-party valuations, internal QC, and fraud detection to manage risk across multiple states The difference between equity members and note holders, including return structure, payout timing, and priority in the waterfall How origination fees, extension fees, leverage, and loan sales can contribute to fund-level returns Why redemption policies matter in debt funds and how managers balance investor liquidity with protecting the fund as a whole Disclaimer The content of this podcast is for informational purposes only. All host and participant opinions are their own. Investment in any asset, real estate included, involves risk, so use your best judgment and consult with qualified advisors before investing. You should only risk capital you can afford to lose. Past performance is not indicative of future results. This podcast may contain paid advertisements or other promotional materials for real estate investment advisers, investment funds, and investment opportunities, which should not be interpreted as a recommendation, endorsement, or testimonial by PassivePockets, LLC or any of its affiliates. Viewers must conduct their own due diligence and consider their own financial situations before engaging with any advertised offerings, products, or services. PassivePockets, LLC disclaims all liability for direct, indirect, consequential, or other damages arising out of reliance on information and advertisements presented in this podcast.

Hot on the heels of I Built You A Tower — Death Cab for Cutie's 11th album, released earlier this month — bassist and founding member Nick Harmer tells us why this LP is the band's loudest in a long time. Plus, a deep dive into his personal record-hunting habits, how the group culled through nearly 100 demos to shape this release, and pinpointing the connecting tissue between Tower's themes of grief, apathy and change. Tour dates, socials and more are available at deathcabforcutie.com.

Tireless synth-funklordz Chromeo had one goal in mind as they crafted Business Casual, their most presentable LP - make keyboard songs so infectious that even Michael Jackson would guest sing the hooks if heard - Follow the Rockwell Aesthetic. Never happened - but Chromeo are still awesome and the most reliable summer music festival late-night set artist in the game. When it's 2am in the Legionnaire Tent and you're putting glow sticks in your mouth and doing bumps of K off the backside of a frisbee, Chromeo is probably on that stage.

Where's the boundary between song and speech? When does something cross the threshold and go from a conversation into a groove? When does the beat drop? One of my favorite musicians, Mononeon, has a whole video series blurring this line.(Mononeon… talk about an inheritor to the FUNK!)Stand up comics. Podcasts. Political speeches. The only way they work is by adding some music to the plain ole' words. But this ain't a blog post. It's a podcast, so put it on and let me sing!For 30% off your first year with DistroKid to share your music with the world click ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠DistroKid.com/vip/lovemusicmore⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Break through your keto or low carb plateau and optimize your heart health by booking a free consultation call with Robert Sikes here: https://www.ketobodybuilding.com/call.Your normal cholesterol is hiding a deadly secret inside your chest. Millions of fit men have massive heart plaque while their doctors say they are completely fine. In episode 892 of the Savage Perspective Podcast, host Robert Sikes and guest Dr. Josh Osborne expose the real truth about cardiovascular disease. Having good blood test numbers means nothing if your blood vessels are sticky and inflamed. Dr. Josh Osborne explains how a fast AI cardiac CT scan spots hidden soft plaque years before a fatal heart attack or stroke happens. Traditional stress tests and neck scans miss the danger. Learn how to shrink arterial plaque today.Visit Clear Cardio for more info: https://clearcardio.com/Get Keto Brick: https://www.ketobrick.com/Subscribe to the podcast: https://open.spotify.com/show/42cjJssghqD01bdWBxRYEg?si=1XYKmPXmR4eKw2O9gGCEuQChapters0:00 - Who Is Dr. John Osborne? | The Harvard Cardiologist Disrupting Medicine1:20 - Why Your Doctor's Heart Tests Are Useless | The Stage 4 Cancer Analogy3:09 - What Is an AI Cardiac CT Scan? | Seeing Heart Plaque in 3D6:00 - The #1 Killer in America | Shocking Cardiovascular Disease Statistics8:34 - When Should I Get a Heart Scan? | The "Cardiac Colonoscopy" Explained11:32 - Is a Cardiac Stress Test Accurate? | The "Healthy Heart" Lie15:38 - Are CIMT Ultrasounds Worth It? | Why Neck Scans Miss Heart Plaque18:52 - How Does a Cardiac CT Scanner Work? | Inside the 1-Second Ferrari Machine23:29 - DEXA Scan vs CT Scan | The Truth About Hidden Visceral Organ Fat28:27 - What Causes Arterial Plaque? | Hidden Risk Factors & Autoimmune Disease32:45 - Why Doesn't Insurance Cover Heart Scans? | The Medical Data Trap36:13 - How Much Does a Cardiac CT Scan Cost? | The $6,000 Prevention Strategy40:20 - Does High Cholesterol Cause Heart Disease? | The Inflammation Debate44:55 - How to Shrink Arterial Plaque | Proven Ways to Reverse Heart Disease48:47 - Should You Take a Statin Prophylactically? | The Broken Healthcare System54:55 - What Is a Calcium Score Test? | The $100 Heart "Mammogram" Explained1:00:50 - Why Do Fit People Have Heart Attacks? | Lp(a) and ApoB Blood Tests1:04:42 - How AI Detects Soft Plaque | Seeing 2,000 Shades of Gray in Your Heart1:06:56 - Where to Get an AI Heart Scan | Booking With Clear Cardio

We're back and talking hardcore. This time around, we're rolling out a list of the top 100 best hardcore records of the 2010s. You know what that means: NEG, TUI, Mindforce, Rival Mob, Warthog, The Flex, The Repos...we're going deep.There is a massive Substack post where every record is broken down. Check it here: https://185milessouth.substack.com/Support the pod: https://www.patreon.com/185milessouthCheck the website: https://www.185milessouth.com/We are on Substack writing about punk and hardcore: https://185milessouth.substack.com/Get at me: 185milessouth@gmail.comCheck out Zack's band, SUBVERSIVE INTENT: https://rebirthrecordsphl.bandcamp.com/album/subversive-intent-s-tBuy their new LP: https://rebirthrecords.bigcartel.com/product/subversive-intent-st-lpCheck Out Kev's band, FALSE SALVATION:https://rebirthrecordsphl.bandcamp.com/album/false-salvation-through-shards-of-glassIntro track: The Rival MobOutro Track: InfernöhSupport the show

Keith sits down with Doug Robinson to discuss growing up in New Jersey, discovering the local scene, joining The Sleeping at just 18 years old, the early days of the band, signing with Victory Records and the band's experience on the label. We also discuss the formation of HELD. by The Sleeping members Doug Robinson and Sal Mignano with Doug stepping into the guitar player and vocalist role, how the band linked up with Josh Eppard of Coheed and Cambria as drummer for the band, the making of their debut LP "Grey", the creative process and themes behind the LP, recording with Jon Markson, signing with MNRK Heavy, what's next for HELD. and more. Intro - 0:00 - 5:13 Doug Robinson Interview - 5:14 - 1:17:25

The London-based art rock band, Mary in the Junkyard, is getting ready to release their debut album after four years of trying to make sense of strange things in life through music. “I think that life is very surreal,” says the vocalist of the group, Clari Freeman-Taylor, as she explains why she enjoys “writing about things that may be a little bit unsettling”. Nothing about the order of life is rehearsed, so why should their music be? Their practice relies heavily on their songwriting and arranging rituals where they carefully piece each layer of sound together. But preparations for live performances are enforced with a spirit of spontaneity, which, as the viola and bass player Saya Barbaglia points out, is a big part of their sound.  The duo blurred the rigid lines of classical music together as they grew into their teenage years with rock music. They traded hours of sight-reading for jam sessions that led to endless scraps of ideas. Those ideas would eventually become fully fleshed-out songs with the addition of drummer David Addison to the band.  Mary in the Junkyard's upcoming LP, Role Model Hermit, carries hints of Freeman-Taylor and Barbaglia's classical music background, as dense string arrangements pop up every now and then. But in our studio, the trio reveals the core of each song they perform: raw, skeletal, dark, and light, all at the same time. (- Sırma Munyar) Setlist: 1. New Muscles 2. Myrtle 3. Blood Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Mitchell Jacobs has worked cargo theft at Walmart, security at Halliburton and United Airlines, and now runs safety and security for Lennox. He sat down with TalkLPnews Editor-in-Chief, Amber Bradley, to talk about the thing that actually keeps him up at night: a whole trailer can vanish off your dock and you won't know for hours. His fix starts with something most leaders skip, which is standing still on the floor long enough to watch two associates try to check in 30 trucks an hour while you ask them to be perfect. He also has a warning. Criminals are already using AI to mine broker boards and build fake bills of lading, and LP is too slow to catch up. Plus the leadership lesson he got from a YMCA boardroom in the 1980s, and why a closed case stopped feeling like a win.

308 - From 52 Houses to Fund Manager: How Tom St. John Built a Portfolio Powered by Discipline, Loss, and Unshakeable Due Diligence What happens when a single telescope changes everything? For Tom St. John, watching his father retire after 32 years at a power plant with nothing but a telescope as a gift was the moment that cracked his world open. That telescope became a symbol of what following the rules without building real assets actually gets you. Tom made a vow to find another way, and what followed was a decades-long journey through single-family rentals, multifamily acquisitions, devastating loss, and hard-won wisdom that now fuels NorthCorp Capital, his private capital allocator and fund management firm based in Toledo, Ohio. Tom's story is not a highlight reel. He built a portfolio of 52 single-family homes, auctioned off nine of them at minimum bids just to scrape together a down payment on his first multifamily deal, and then lost his brother and maintenance manager in a tragic car accident that forced him to run everything alone for six years. He later lost six figures as a limited partner by trusting the wrong operator, and that painful lesson transformed him into one of the sharpest due diligence practitioners in the private markets space. Today, Tom vets operators for a living, manages funds across multifamily, real estate debt, and private credit, and delivers annualized returns of 12% to accredited investors who want the economic benefits of real estate without the operational headaches. If you are a real estate investor wondering whether to stay in the grind of active operations or start thinking about passive investing and private alternatives, this episode will shift how you see both. Tom breaks down exactly how he stress-tests deals, what operator red flags look like in the wild, how to increase net operating income by improving tenant experience, and why significance matters more to him than success. Whether you are just starting out or ready to level up into multifamily or fund investing, you will walk away with a smarter framework and a deeper sense of what building a lasting portfolio actually requires. 5 Powerful Takeaways Auctioning nine houses to fund his first multifamily deal taught Tom that letting go of smaller assets strategically is often the fastest path to real scale, and that conviction in the right next move matters more than comfort. After losing six figures to the wrong operator, Tom learned to invest in people first and deals second, focusing on track record through difficult markets, conservative underwriting, and whether operators earn based on performance rather than fees. Increasing net operating income does not start with jacking up rents. It starts with building community, improving tenant experience, and making residents want to stay, because one lease renewal is worth far more than a $100 rent bump. High-pressure sales tactics from operators ("We're 85% subscribed, invest now!") are a major red flag that signals someone is in the business of raising money, not managing property. Tom's shift from pursuing growth and net worth to pursuing income replacement and significance is a mindset upgrade that every investor scaling toward time freedom needs to hear. About the Guest Tom St. John is the founder of NorthCorp Capital LLC, a private capital allocator and fund management firm based in Toledo, Ohio, with over 20 years of experience in real estate and private markets. Tom began his real estate journey in 2005 after watching his father retire from 32 years at a power plant with almost nothing to show for it, which set him on a relentless path toward financial independence. He built a 52-unit single-family portfolio, transitioned into multifamily, and navigated serious personal losses including the death of his brother and a six-figure loss as a limited partner, each of which sharpened his operational and due diligence skills. Today Tom manages funds across multifamily syndications, real estate debt, and private credit, helping accredited investors access vetted operators and stable income streams. He is known for his thorough stress-testing of deals, his deep operator relationships, and his conviction that significance is a more meaningful measure of success than net worth. 00:00 REIGN Podcast Intro 00:53 BRRRR Method Breakdown 02:51 Meet Tom St John 04:41 Telescope Turning Point 07:32 Learning Through Books 09:26 First Rental Deal 10:05 Scaling Single Family Ops 12:40 Auction to Go Multifamily 14:21 Why Multifamily Scales 16:52 From Operator to Investor 18:09 Boosting NOI With Amenities 21:19 Vetting Operators as LP 23:41 Losing His Brother and Rebuilding 26:29 Vetting Operators 27:57 Underwriting Stress Tests 29:16 Red Flags and Trust 31:04 NorthCorp Capital Today 34:13 Fund Structure Explained 35:38 Podcast and Guests 38:06 Badass Framework 38:12 Books and Advice 41:21 Drive Goals Systems 44:58 Significance and Wrap Up   Resources & Websites Mentioned NorthCorp Capital: https://northcorpcapital.com Tom St. John on LinkedIn: search Thomas St. John Book recommendation: "Parable of the Pipeline" by Burke Hedges Book mentioned: "Who Not How" Book mentioned: "Buy Back Your Time" by Dan Martell Book mentioned: "Rich Dad Poor Dad" TriVest (investor portal and fund administration platform) To learn more about Jen Josey, visit https://www.therealjenjosey.com/ To join REIGN, visit https://www.reignmastermind.com/ Stuff Jen Josey Loves: https://www.reignmastermind.com/resources Buy Jen Josey's Book: From Beginner to Badass: https://a.co/d/bstKlby New episodes drop every Monday Morning at 6am EST. See you next time.

The conversation delves into the misunderstood nature of LP little a, the panic and fear surrounding it, the nuanced biological roles of LP little a, the lack of definitive human outcome trials, the structural complexity of LP little a, the influence of genetics on LP little a, and the practical implications of LP little a results.TakeawaysLP little a is often misunderstood and associated with panic and fearThe biological roles of LP little a are more nuanced than commonly portrayedChapters00:00 Practical Implications of LP Little A Results

The March 2026 ACC/AHA Guideline on the Management of Dyslipidemia made a major pivot regarding Lipoprotein(a) by establishing a formal recommendation for universal screening in adults. This 2026 guideline, published in the Journal of the American College of Cardiology, issued a Class 1 recommendation stating that every adult should have their Lp(a) measured at least once in their lifetime. Because Lp(a) levels are genetically determined and remain highly stable throughout a person's life, a single lifetime check is sufficient for the vast majority of the population to establish their baseline risk. Well, that's great for Family medicine or internal medicine, but how does that affect us in women's health? Well, it's complicated: lipoprotein(a) has been associated with an increased risk of VTE and has also been associated, in some studies, with FGR, preeclampsia, and preterm birth! So, can these patients receive oral contraceptives? What about Perioperative and postop care? Do these patients require anticoagulation? What about pregnancy- is LDA recommended here? And lastly, what about TXA use in patients with HMB? This podcast topic comes from one of our podcast family members who is an OBGYN military personnel caring for our wonderful troops overseas. Listen in for details!16% OFF TONA ACTIVE WEAR PROMO: https://tonaactive.com/discount/CHAPANOSPINOBG1. Ezzat, D., Lopez, D. M., Claggett, B. L., Li, L., Mohammadnia, N., Schuermans, A., Hemeryck, J., Chang, A., Murillo, S., O'Donoghue, M. L., Bikdeli, B., Yu, Z., Natarajan, P., Patel, A. P., Pabon, M. A., & Honigberg, M. C. (2026). Lipoprotein(a) and incident venous thromboembolism in pre- and postmenopausal women, and in men. European Heart Journal, ehag252. https://doi.org/10.1093/eurheartj/ehag2522.ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Dyslipidemia Writing Committee. (2026). 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation, 153, e1155–e1300. https://doi.org/10.1161/CIR.00000000000014233. CDC MEC 4. Prevention of Venous Thromboembolism in Gynecologic Surgery: ACOG Practice Bulletin, Number 232. Obstetrics and Gynecology. 2021. Committee on Practice Bulletins—Gynecology5. Sofi F, Marcucci R, Abbate R, Gensini GF, Prisco D.Lipoprotein(a) as a Risk Factor for Venous Thromboembolism: A Systematic Review and Meta-Analysis of the Literature.Seminars in Thrombosis and Hemostasis. 2017. Dentali F, Gessi V, Marcucci R, et al. Lipoprotein (A) and Venous Thromboembolism in Adults: The American Journal of Medicine. 2007.

What happens after you die? It's a question that has fascinated humanity for thousands of years. Today's guest has an answer that might surprise you.  Dannion Brinkley has been clinically dead multiple times, and what he learned from those experiences led him to one extraordinary conclusion: nobody ever dies. Dannion is the bestselling author of Saved by the Light and Secrets of the Light, a hospice volunteer with nearly 50 years of service, and one of the world's most well-known near-death experience survivors.  After being struck by lightning in 1975 and clinically dead for 28 minutes, Dannion says he experienced what he calls a panoramic life review that completely transformed the course of his life. Dannion has devoted his life to helping people face death without fear. He has spent more than 34,000 hours at the bedside of veterans in the VA, provided hospice support to over 2,000 people during their final days, and helped build one of the largest end-of-life volunteer programs for veterans, the Brinkley Center Foundation. In our conversation, Dannion shares what he has learned from decades spent helping people navigate life's final transition, why he believes no one truly dies, what happens during the panoramic life review, and how we can live in a way that brings more love, service, and meaning to the people around us. KEY TAKEAWAYS What Dannion Experienced From the Lightning Strike The One Question We All Will Eventually Face The Visions Dannion Saw About The Future What Happens in 95% of Near-Death Experiences  Dannion Describes His Other Near-Death Experiences When You Feel The Impact Of Your Actions In An Instant What People Most Need At The End Of Life What Dannion Says To Skeptics Dannion's Message For Living Without Fear How To Support Caregivers And Loved Ones The Power Of Each Breath Get The Full Show Notes To get full access to today's show notes, including audio, transcript, and links to all the resources mentioned, visit MiracleMorning.com/640 Subscribe, Rate & Review I would love if you could subscribe to the podcast and leave an honest rating & review. This will encourage other people to listen and allow us to grow as a community. The bigger we get as a community, the bigger the impact we can have on the world. To subscribe, rate, and review the podcast on iTunes, visit HalElrod.com/iTunes. Get Access to Hal's Books and the Miracle Morning App For access to Hal's Miracle Morning books, CLICK HERE.  To upgrade your morning routine, CLICK HERE to download the Miracle Morning App.  Book Hal to Speak At Your Event! If you'd like to book Hal to speak at your next event, CLICK HERE. Connect with Hal Elrod Facebook Twitter Instagram LinkedIn YouTube TikTok   Copyright © 2026 Miracle Morning, LP and International Literary Properties LLC  

Most of us have had that moment where we get our bloodwork back and shake our heads. We're still our active, health‑minded selves and out of nowhere—rising LDL, ApoB, A1C, and maybe blood pressure and Lp(a), too. This week, preventive cardiology dietitian Michelle Routhenstein joins us to unpack the cardiometabolic chaos and what's really driving it. She explains estrogen's protective role in lipids and blood pressure, why standard risk calculators and even calcium scores can miss women's disease, and which advanced labs are worth asking for. We also dig into how under‑fueling and low‑carb diets can worsen cardiometabolic health and plaque; why complex carbs, fiber, fermented foods, and gut health matter so much; and how to approach protein, red meat, electrolytes, nitric oxide, and statins in a personalized, empowering way—remembering that 80–90% of heart disease remains preventable when women get the right information and advocate for themselves.Michelle Routhenstein, MS, RD, CDCES, CDN is a preventive cardiology dietitian and founder of Entirely Nourished, a virtual practice focused on personalized, science-based nutrition for heart health. With over 14 years of experience, she helps people improve cardiometabolic risk and manage conditions like atherosclerosis, heart failure, and atrial fibrillation using a whole-person approach. She holds Bachelor's and Master's degrees in Clinical Nutrition from New York University, serves on the Forbes Health Advisory Board and the Medical Advisory Committee for the National Menopause Foundation, and is the author of The Truly Easy Heart-Healthy Cookbook and Simple Meal Solutions for High Blood Pressure. Her work has been featured in outlets including Forbes Health, Fox News, Prevention, Women's Health, and Good Housekeeping, and she works with clients virtually from New York via www.entirelynourished.comJoin us at Feisty Fest September 18-20, 2026: https://feisty.co/events/feisty-fest/Sign up for our FREE Feisty 40+ newsletter: https://feisty.co/feisty-40/Learn More about our 2026 Feisty Events, including Bike Camps and Cycling Trips: https://feisty.co/events/Follow Us on Instagram:Feisty Menopause: @feistymenopauseHit Play Not Pause Facebook Group: https://www.facebook.com/groups/807943973376099Support our Partners:Midi Health: You Deserve to Feel Great. Book your virtual visit today at https://www.joinmidi.com/Previnex: Get 20% off your order with code FEISTYBRAIN at https://www.previnex.com/ Wahoo: Use the code FEISTY2026 to get a free Headwind Smart Fan (value $300) with the purchase of a Wahoo KICKR RUN at https://shorturl.at/WVhdrCozy Earth: Use Code HITPLAY at https://cozyearth.com/ for up to 20% off